Timolol

Pharmacogenomic Information in the Context of the FDA-Approved Drug Label*

Timolol is a non-selective beta adrenergic agonist applied to the eye to reduce intraocular pressure. It is metabolized via CYP2D6.

The FDA recommends, but does not require, genetic testing prior to initiating or reinitiating treatment with Timolol (Istalol).

Excerpt from the Timolol (Istalol) drug label:
"Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with quinidine and timolol, possibly because quinidine inhibits the metabolism of timolol via the P-450 enzyme, CYP2D6."

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Timolol (Istalol) drug label PDF.